dc.contributor.author |
Gallwitz, Baptist |
|
dc.date.accessioned |
2019-06-04T07:53:48Z |
|
dc.date.available |
2019-06-04T07:53:48Z |
|
dc.date.issued |
2017 |
|
dc.identifier.issn |
1744-764X |
|
dc.identifier.uri |
http://hdl.handle.net/10900/89283 |
|
dc.language.iso |
en |
de_DE |
dc.publisher |
Taylor & Francis Ltd |
de_DE |
dc.relation.uri |
http://dx.doi.org/10.1080/14740338.2017.1382471 |
de_DE |
dc.rights |
info:eu-repo/semantics/closedAccess |
|
dc.subject.ddc |
610 |
de_DE |
dc.title |
A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes |
de_DE |
dc.type |
Article |
de_DE |
utue.quellen.id |
20190131163842_04262 |
|
utue.publikation.seiten |
1399-1405 |
de_DE |
utue.personen.roh |
Gallwitz, Baptist |
|
dcterms.isPartOf.ZSTitelID |
Expert Opinion on Drug Safety |
de_DE |
dcterms.isPartOf.ZS-Issue |
12 |
de_DE |
dcterms.isPartOf.ZS-Volume |
16 |
de_DE |
utue.fakultaet |
04 Medizinische Fakultät |
de_DE |